Roxtrocin

Quick links to important sections

Roxtrocin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roxtrocin

What is Roxtrocin? (Overview)

Property Description
Active Ingredient Roxithromycin
Form Oral Tablet, Suspension (market dependent)
Pharmacological Class Macrolide Antibiotic
Common Use Treatment of specific bacterial infections
Origin Semi-synthetic derivative of erythromycin

Roxtrocin is a prescription medicine containing the active ingredient roxithromycin, which is classified as a macrolide antibiotic. This class of drugs is used to treat a variety of infections caused by susceptible bacteria. Roxithromycin is chemically characterized by a large 14-membered macrocyclic lactone ring structure.

Roxithromycin is a semi-synthetic derivative of the older antibiotic erythromycin. The chemical modification was performed to enhance the drug's absorption and provide a longer duration of therapeutic effect in the body. This improved pharmacokinetic profile is a key distinguishing feature of roxithromycin compared to the original compound.

Roxithromycin is effective against common respiratory pathogens like Streptococcus pneumoniae and Haemophilus influenzae and is often utilized for treating community-acquired respiratory tract infections. As a macrolide, roxithromycin works by binding to the 50S subunit of the bacterial ribosome, which inhibits the bacteria's ability to create proteins necessary for growth and replication. This mechanism helps the body halt the infection's spread.

It is critical to understand that Roxtrocin is a prescription-only (Rx) medicine and is ineffective against viral illnesses, such as the common cold or flu. It must only be taken under the guidance of a healthcare professional to treat a confirmed bacterial infection.

What side effects are possible with Roxtrocin?

Possible Side Effects and Safety Information for Roxtrocin

Roxtrocin (roxithromycin), a macrolide antibiotic, has a known safety profile documented in regulatory sources, encompassing common side effects and rare but serious adverse reactions.

Adverse Reaction Scope

Common Adverse Reactions: The most frequently reported side effects are associated with the gastrointestinal system. These typically include nausea, vomiting, abdominal pain, diarrhea, and decreased appetite. Skin reactions such as rash and pruritus (itching) are also commonly noted.

Serious and Clinically Significant Adverse Reactions: Although rare, several reactions are deemed serious and require immediate attention, including:

  • Cardiac Events: Prolongation of the QT interval, which can lead to life-threatening ventricular arrhythmias, including Torsades de Pointes.
  • Severe Hypersensitivity: Anaphylaxis, angioedema (swelling of the face or throat), and serious bullous skin reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Gastrointestinal: Severe, persistent diarrhea that may indicate Clostridium difficile-associated diarrhea (pseudomembranous colitis).
  • Hepatobiliary: Liver function abnormalities, which may rarely progress to severe hepatic disorders like cholestatic hepatitis with or without jaundice.
System-Organ Class Examples of Adverse Reactions (Official Documentation)
Gastrointestinal Nausea, Vomiting, Diarrhea, Abdominal pain, Flatulence
Skin Disorders Rash, Pruritus, Urticaria, SJS, TEN
Nervous System Headache, Dizziness, Taste/Smell disorders, Paresthesia
Hepatobiliary Abnormal liver function values, Jaundice, Hepatitis

Safety-Related Restrictions

Contraindications: Roxtrocin is strictly contraindicated in individuals with known hypersensitivity to roxithromycin or any other macrolide antibiotics (e.g., erythromycin, azithromycin). It is also contraindicated for concurrent use with vasoconstrictive ergot alkaloids (like ergotamine) due to the risk of severe vasoconstriction (ergotism) with possible tissue damage. Patients with severe hepatic impairment should not take this medication.

Cautionary Considerations: Caution is advised in patients with existing hepatic impairment, as the drug's half-life may be increased. Due to the risk of QT prolongation, the benefit/risk must be weighed for patients predisposed to cardiac arrhythmias or those taking other drugs known to prolong the QT interval.

Overdose and Emergency Response

Overdose with Roxtrocin (roxithromycin) requires immediate emergency medical attention due to the potential for severe, life-threatening effects. Official regulatory documents list nausea, vomiting, epigastric pain, and diarrhea as documented clinical presentations of overdose. High exposure may also result in central nervous system effects such as confusion and hallucinations.

The most serious risk involves the cardiovascular system, specifically the potential for QT interval prolongation and subsequent severe ventricular arrhythmias, including Torsades de pointes [Arrow – Roxithromycin - Medsafe]. This potentially life-threatening outcome necessitates urgent medical evaluation.

Regulatory guidance mandates that an individual seek medical attention immediately or contact a Poison Control Centre. Management is officially restricted to symptomatic and supportive treatment, as no specific antidote is known. Procedures may include gastric lavage and the administration of fluids. Due to cardiac risk, ECG monitoring is warranted [Roxithromycin Sandoz® - NPS]. Patients with impaired hepatic function are noted to have an increased serum half-life, which may prolong the effects of an overdose.

Therapeutic Uses of Roxtrocin

Quick Facts: Roxtrocin

  • May be used to address respiratory tract infections.
  • Indicated for certain soft tissue infections.
  • Applicable for specific genitourinary tract infections.

Roxtrocin (roxithromycin) is a medication utilized in the management of infections caused by susceptible organisms. The therapeutic application of this agent generally centers on supporting the resolution of various bacterial conditions.

This medication is primarily indicated for use in the management of upper and lower respiratory tract infections, such as certain pneumonias and acute exacerbations of chronic bronchitis. It may also be applied in therapeutic plans for specific ear, nose, and throat infections.

Roxtrocin is further used to address certain skin and soft tissue infections and may be incorporated into regimens for managing genitourinary tract infections caused by susceptible bacteria. Roxtrocin is an appropriate option for these specific therapeutic domains when a macrolide class agent is deemed suitable by a healthcare professional.

Regulatory References

  1. FDA therapeutic overview for Roxithromycin

Eligibility and Restrictions for Use

Roxtrocin is generally considered eligible for use in adults and adolescents, with no routine dosage adjustments required for the elderly. However, official regulatory labeling establishes clear population constraints and absolute contraindications for the medicine.

Roxtrocin is strictly contraindicated in patients with known hypersensitivity to macrolide antibiotics or any component of the formulation. Absolute exclusion applies to individuals with severe hepatic impairment (severe liver disease) and those with a history of congenital or acquired QT interval prolongation. Furthermore, the medicine must not be administered concurrently with ergot alkaloids (like ergotamine) or certain other drugs known to prolong the QT interval.

Use is restricted in patients with mild to moderate hepatic impairment, which necessitates specific clinical caution. Patients with pre-existing cardiac risk factors, such as significant bradycardia, also require careful assessment. Roxtrocin is generally not recommended for children under the age of six years. For pregnant and breastfeeding patients, use is restricted and only permitted if the clinical need explicitly justifies the potential risks, as outlined by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Roxtrocin (roxithromycin) through specific pharmacokinetic and pharmacodynamic constraints. Co-administration is formally contraindicated with certain medicines due to the risk of severe outcomes, as explicitly documented in prescribing information.


Contraindicated Combinations

The following substances are prohibited for co-administration due to officially documented interaction risks:

  • Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine): Interaction carries the risk of severe vasoconstriction.
  • Astemizole, Cisapride, and Pimozide: Co-administration is contraindicated due to the potential for increased drug levels, leading to the risk of QT interval prolongation and severe cardiac arrhythmias.

Other Clinically Significant Interactions

Roxithromycin is a weak inhibitor of the CYP3A4 enzyme, which can increase the exposure of certain co-administered drugs. This includes an officially documented increase in the plasma concentration of Midazolam.

Other medicines requiring close monitoring due to altered exposure include:

  • Warfarin (and other anticoagulants): Official reports note an increase in INR/Prothrombin Time.
  • Digoxin and Theophylline: Increased plasma concentrations have been documented, requiring level monitoring.

Interaction with Food and Condition-Specific Notes: Food delays the absorption of roxithromycin, which is why official administration instructions recommend taking it on an empty stomach. Furthermore, in patients with severe hepatic impairment, the drug's serum half-life is increased, and a dose reduction is formally addressed in some regulatory labels.

Mechanism of Action

How Roxtrocin Works: Mechanism of Action


Targeted Inhibition of Bacterial Protein Synthesis

Roxithromycin, a macrolide, exerts its function as an inhibitor by means of a reversible, non-covalent binding to the 23S ribosomal RNA component within the 50S ribosomal subunit of susceptible bacteria. This molecular interaction physically obstructs the peptide exit tunnel, thereby inhibiting the crucial process of polypeptide chain elongation and leading directly to the cessation of all essential bacterial protein synthesis.


Establishing the Bacteriostatic State

The blockage of protein production immediately halts bacterial proliferation; this is the resulting physiological consequence of the drug's mechanism. This action establishes a bacteriostatic state—meaning it prevents the bacteria from multiplying and spreading—rather than immediately causing cell death, resulting in a reduction of the bacterial load against the host system.


Understanding Mechanistic Limitations

The drug’s mechanism is constrained by biological factors such as genetic ribosomal methylation and the activity of bacterial efflux pumps, which actively transport the drug out of the cell. These mechanisms prevent the required saturation of the 50S subunit, structurally limiting the drug's ability to exert its inhibitory physiological effect against certain bacterial strains.

Dosage and Administration Information

Administration Methods

Roxtrocin is typically administered orally. The tablets are intended to be swallowed whole with a sufficient amount of liquid, such as a glass of water.

Timing and Food Intake

To ensure optimal absorption of the active substance, it is generally recommended to take the medication at least 15 minutes before a meal. Consistency in the timing of administration helps maintain steady levels of the medication in the system.

Duration of Use

The length of the treatment course is determined based on the nature of the condition being addressed and the clinical response observed. It is standard practice to continue the application for a specific period even after the initial symptoms have subsided to ensure the stability of the results.

Handling and Storage

Tablets should be kept in their original packaging until the time of use to protect them from environmental factors. Store the medication in a cool, dry place away from direct sunlight and out of the reach of children.

Recent Clinical Evidence

Recent Clinical Evidence

Research Focus and Scope

Research has explored the potential for this drug to be linked to changes in reported muscle spasm frequency, and studies have examined outcomes related to pain and function in individuals with chronic lower back pain who used its combination with other medications.

The majority of studies focus on administration periods of up to 12 weeks for acute musculoskeletal conditions. Research has investigated whether a combination approach is associated with different outcomes compared to monotherapy in individuals experiencing severe spasms.


Key Findings from Clinical Trials

Efficacy and Outcome Measures

According to one key study, the drug's tolerability was evaluated in a specific group of individuals, and the research reported findings related to changes in the frequency and severity of muscle spasms observed over a 12-week period.

Other studies evaluated the drug's relationship with quality of life metrics, such as scores related to sleep disturbance linked to muscle pain. Findings were mixed regarding the statistical significance of these quality of life changes.

Research comparing this drug to older treatments has explored differences in reported side effect profiles and dosing schedules.

Safety and Tolerability Profiles

Drowsiness and dizziness were frequently identified as adverse events in study reports. Studies examining the drug's use reported that it may be linked to drowsiness. Drowsiness was noted in study results as a reported consequence.

Studies have examined the drug's use in individuals with pre-existing liver issues, and some research reports findings suggesting a potential for liver function changes. It is important to note that studies were not designed to specifically track all long-term outcomes, and therefore evidence regarding long-term safety remains limited.

Key Studies & References

  1. Cyclobenzaprine Use in Patients with Liver Disease: A Retrospective Observational Study on Hepatic Function Tests

Frequently Asked Questions (FAQ)

Common questions about Roxtrocin (FAQ)


Q: What infections are commonly treated with Roxtrocin?

A: Official product information states that Roxtrocin is approved for treating specific bacterial infections across several body systems. This includes infections of the upper respiratory tract (like pharyngitis, tonsillitis, and otitis media), the lower respiratory tract (such as bronchitis and pneumonia), and certain skin and soft tissue infections.


Q: Does Roxtrocin work for sinus infections?

A: Yes, according to official regulatory documents, Roxtrocin is indicated for treating specific upper respiratory tract infections, including sinusitis. It is used when the infection is caused by bacteria that are susceptible to this type of antibiotic.


Q: Is Roxtrocin similar to erythromycin or azithromycin?

A: Roxtrocin's active ingredient, roxithromycin, is classified as a macrolide antibiotic. This makes it chemically similar to drugs like azithromycin. It is related to the older antibiotic erythromycin, being a derivative designed to offer improved characteristics. Official information also notes that cross-resistance is possible between roxithromycin and other macrolides.


Q: What's the difference between Roxtrocin and penicillin?

A: Roxtrocin and penicillin belong to different classes of antibiotics and work in different ways. Roxtrocin is a macrolide that stops bacteria from making essential proteins. Penicillin is a beta-lactam that prevents bacteria from building their cell walls. Because Roxtrocin belongs to a different drug class than penicillin, it is sometimes used for patients who have an allergy to penicillin-class medications.


Q: Can Roxtrocin be used for skin infections or acne?

A: Regulatory documents indicate that Roxtrocin is approved for the treatment of certain skin and soft tissue infections. This includes certain bacterial skin conditions, such as pyoderma and impetigo.


Q: Is it normal to feel nauseous or have stomach pain after taking Roxtrocin?

A: Yes, regulatory documents list nausea, vomiting, and abdominal pain as among the most frequently reported common adverse reactions. These effects are linked to how the drug is processed by the body and are officially listed as very common.


Q: Do you get diarrhea often when on a course of Roxtrocin?

A: Diarrhea is officially noted as a frequently reported, common adverse reaction to Roxtrocin. While usually mild, official warnings note that severe, persistent diarrhea may rarely occur and can be a sign of a serious condition, such as Clostridium difficile-associated diarrhea.


Q: Can Roxtrocin make you feel tired or dizzy?

A: Official regulatory documents list dizziness and headache as less common side effects affecting the nervous system. Although general tiredness (fatigue) isn't consistently listed as a direct side effect, dizziness may affect your ability to function normally.


Q: Are there any foods or drinks I should avoid while taking Roxtrocin?

A: The official product information specifically recommends avoiding alcohol consumption during treatment with Roxtrocin to prevent potential side effects. Regulatory documents also note that antacids containing aluminum or magnesium should not be taken simultaneously with Roxtrocin, as this may impact absorption.


Q: How long after finishing the prescription is Roxtrocin out of your system?

A: The amount of Roxtrocin in the body decreases over time, a process measured by its half-life. Official pharmacokinetic data indicates that the half-life of the drug is approximately 12 hours in healthy adults.


Q: Can children take Roxtrocin, and is there a liquid version?

A: Roxtrocin is generally not recommended for children under 6 years of age. For children who do meet the age/weight requirements for use, an oral suspension (liquid) form is available in many regions as an alternative to tablets.


Q: Does Roxtrocin affect the 'good' bacteria in your gut?

A: As an antibiotic, Roxtrocin targets susceptible bacteria. The regulatory warnings about diarrhea confirm that the drug can disrupt the normal balance of helpful bacteria in the gut. As an antibiotic, it is intended only for confirmed bacterial infections, which explains why it can disrupt the balance of normal bacteria.


Q: Why must people with certain heart conditions avoid macrolide antibiotics like Roxtrocin?

A: Roxtrocin is used with caution or is formally contraindicated (prohibited) for people with certain heart conditions. This is due to the potential risk of QT interval prolongation, an effect that increases the risk of developing severe, life-threatening cardiac arrhythmias (irregular heart rhythms).


Q: Does Roxtrocin have a metallic or strange taste?

A: Regulatory documents list taste/smell disorders as a possible adverse reaction. This confirms that a change in taste sensation may occur while taking the medicine.


Q: Can Roxtrocin cause headaches?

A: Yes, official regulatory documents list headache as a less common side effect associated with Roxtrocin. It is noted as an adverse event affecting the nervous system.


Q: What is the difference in how Roxtrocin and amoxicillin are used?

A: Roxtrocin (a macrolide) and amoxicillin (a penicillin-class drug) are both used to treat bacterial infections, but they target different spectrums of bacteria. Roxtrocin is sometimes used for patients who have a known penicillin allergy, as it belongs to a different class of antibiotics.


Q: How is Roxtrocin absorbed by the body?

A: Official information indicates that Roxtrocin is rapidly absorbed when taken orally. To achieve optimal absorption, it is important to take the medicine on an empty stomach.


Q: Can Roxtrocin cause insomnia or sleep issues?

A: While Roxtrocin's side effect profile lists effects like dizziness and headache that might indirectly affect sleep, insomnia itself is not consistently listed as a common adverse reaction in official regulatory documents.

How should Roxtrocin be stored and disposed of?

Storage and Disposal of Roxtrocin (Roxithromycin)

The storage and disposal instructions for Roxtrocin are strictly defined by regulatory authorities to maintain the product's stability and ensure safe handling.


Official Storage Requirements

Roxtrocin tablets must be stored in a cool, dry place at temperatures not exceeding 25 C or 30 C. The medicine must be protected from light and moisture and should not be frozen.

Tablets should be kept in the blister packaging until the time of use. For safety, Roxtrocin must always be kept out of the sight and reach of children.


Disposal Instructions

Expired or unused Roxtrocin must not be thrown away via wastewater or household waste. Official regulatory instructions mandate consulting a pharmacist for guidance on how to properly discard the unused medicine. These measures are necessary to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Roxtrocin found in:

A-Z Index: